PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus

被引:32
作者
Chan, Liana C. [1 ,3 ]
Gilbert, Aubre [1 ]
Basuino, Li [1 ]
da Costa, Thaina M. [1 ,2 ]
Hamilton, Stephanie M. [1 ]
dos Santos, Katia R. [2 ]
Chambers, Henry F. [1 ]
Chatterjee, Som S. [1 ]
机构
[1] San Francisco Gen Hosp, Div Infect Dis, Dept Med, San Francisco, CA 94110 USA
[2] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil
[3] Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90509 USA
基金
美国国家卫生研究院;
关键词
PENICILLIN-BINDING PROTEINS; BETA-LACTAM RESISTANCE; METHICILLIN RESISTANCE; CEFTAROLINE; CEFTOBIPROLE; MUTATIONS; SUSCEPTIBILITY; INFECTIONS; VIRULENCE; GENE;
D O I
10.1128/AAC.00358-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Staphylococcus aureus is an important cause of both hospital- and community-associated methicillin-resistant S. aureus (MRSA) infections worldwide. beta-Lactam antibiotics are the drugs of choice to treat S. aureus infections, but resistance to these and other antibiotics make treatment problematic. High-level beta-lactam resistance of S. aureus has always been attributed to the horizontally acquired penicillin binding protein 2a (PBP 2a) encoded by the mecA gene. Here, we show that S. aureus can also express high-level resistance to beta-lactams, including new-generation broad-spectrum cephalosporins that are active against methicillin-resistant strains, through an uncanonical core genome-encoded penicillin binding protein, PBP 4, a nonessential enzyme previously considered not to be important for staphylococcal beta-lactam resistance. Our results show that PBP 4 can mediate high-level resistance to beta-lactams.
引用
收藏
页码:3934 / 3941
页数:8
相关论文
共 46 条
[1]   Ceftobiprole:: An extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin [J].
Anderson, Shawn D. ;
Gums, John G. .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (06) :806-816
[2]   Allelic replacement in Staphylococcus aureus with inducible counter-selection [J].
Bae, T ;
Schneewind, O .
PLASMID, 2006, 55 (01) :58-63
[3]   In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus [J].
Baneriee, Ritu ;
Gretes, Michael ;
Basuino, Li ;
Strynadka, Natalie ;
Charnbers, Henry F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) :2089-2096
[4]   A mecA-Negative Strain of Methicillin-Resistant Staphylococcus aureus with High-Level β-Lactam Resistance Contains Mutations in Three Genes [J].
Banerjee, Ritu ;
Gretes, Michael ;
Harlem, Christopher ;
Basuino, Li ;
Chambers, Henry F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) :4900-4902
[5]   Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole [J].
Barbour, April ;
Derendorf, Hartmut .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 :485-495
[6]   Genetic basis of methicillin resistance in Staphylococcus aureus [J].
Berger-Bächi, B .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (9-10) :764-770
[7]   In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program [J].
Biedenbach, Douglas J. ;
Alm, Richard A. ;
Lahiri, Sushmita D. ;
Reiszner, Edina ;
Hoban, Daryl J. ;
Sahm, Daniel F. ;
Bouchillon, Samuel K. ;
Ambler, Jane E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) :343-347
[8]  
Bush K, 2012, REV SCI TECH OIE, V31, P43
[9]   Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy [J].
Casapao, Anthony M. ;
Davis, Susan L. ;
Barr, Viktorija O. ;
Klinker, Kenneth P. ;
Goff, Debra A. ;
Barber, Katie E. ;
Kaye, Keith S. ;
Mynatt, Ryan P. ;
Molloy, Leah M. ;
Pogue, Jason M. ;
Rybak, Michael J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) :2541-2546
[10]   Waves of resistance: Staphylococcus aureus in the antibiotic era [J].
Chambers, Henry F. ;
DeLeo, Frank R. .
NATURE REVIEWS MICROBIOLOGY, 2009, 7 (09) :629-641